Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode

被引:68
作者
Salvadore, Giacomo [1 ]
Viale, Carlos I. [2 ]
Luckenbaugh, David A. [1 ]
Zanatto, Vanessa C. [2 ]
Portela, Luiz V. [2 ]
Souza, Diogo O. [2 ]
Zarate, Carlos A., Jr. [1 ]
Machado-Vieira, Rodrigo [1 ,3 ]
机构
[1] NIMH, Expt Therapeut Mood & Anxiety Disorders Program, NIH, Bethesda, MD 20892 USA
[2] Univ Fed Rio Grande do Sul, Dept Biochem, BR-90035003 Porto Alegre, RS, Brazil
[3] Univ Sao Paulo, Inst & Dept Psychiat, BR-05508 Sao Paulo, SP, Brazil
基金
美国国家卫生研究院;
关键词
Bipolar disorder; Depression; Gout; Mania; Purines; Uric acid; DOUBLE-BLIND; ALLOPURINOL; LITHIUM; EFFICACY; ILLNESS; MODEL;
D O I
10.1016/j.pnpbp.2010.02.027
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Recent evidence suggests that purinergic system dysfunction may play a role in the pathophysiology and therapeutics of bipolar disorder (BPD). Uric acid is a key nitrogenous end product of purine metabolism. In addition to being a potential marker of treatment response, high levels of uric acid may represent a state marker during mania. In this study, we assessed the presence of purinergic dysfunction in 20 treatment-naive first episode patients with BPD who were experiencing a manic episode. Patients were matched with 24 healthy controls. We found that acutely manic patients had significantly higher levels of plasma uric acid (4.85 +/- 1.60 mg/dL) compared to healthy controls (2.96 +/- 0.63 mg/dL, p<0.001; F=28.1). No association between uric acid levels with severity of manic symptoms was observed. These results support the role of purinergic system dysfunction in BPD early in the course of illness, and suggest that this phenomenon is not the result of chronicity or medication exposure. Overall, our findings suggest a novel mechanism in the pathophysiology of BPD. Published by Elsevier Inc.
引用
收藏
页码:819 / 821
页数:3
相关论文
共 16 条
[1]   Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial [J].
Akhondzadeh, Shahin ;
Milajerdi, Mehdi Rafiee ;
Amini, Homayoun ;
Tehrani-Doost, Mehdi .
BIPOLAR DISORDERS, 2006, 8 (05) :485-489
[2]  
[Anonymous], 2002, STRUCTURED CLIN INTE
[3]  
ANUMONYE A, 1968, LANCET, V1, P1290
[4]  
BOWMAN GL, 2010, J ALZHEIMERS DI 0107
[5]   Purinergic signalling and disorders of the central nervous system [J].
Burnstock, Geoffrey .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (07) :575-590
[6]  
De Berardis D, 2008, J BIOL REG HOMEOS AG, V22, P195
[7]   Lesch-Nyhan disease: from mechanism to model and back again [J].
Jinnah, H. A. .
DISEASE MODELS & MECHANISMS, 2009, 2 (3-4) :116-121
[8]  
Kraeplin E., 1921, MANIC DEPRESSIVE INS
[9]  
LORENZI TM, 2009, J AFFECT DISORD 0611
[10]   Therapeutic efficacy of allopurinol in mania associated with hyperuricemia [J].
Machado-Vieira, R ;
Lara, DR ;
Souza, DO ;
Kapczinski, F .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (06) :621-622